^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

EGFR L858R

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
Related tests:
1d
Patient Age and EGFR-positive Non-small Cell Lung Cancer: A Multicenter Retrospective Study. (PubMed, Anticancer Res)
Patients in their 70s and 80s with non-small cell lung cancer were relatively frequently EGFR gene-positive. To avoid missing out on treatment opportunities, EGFR gene testing should also be performed on patients in this age group.
Retrospective data • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR L858R • EGFR exon 19 deletion • EGFR positive • EGFR negative
1d
Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer. (PubMed, Invest New Drugs)
The median PFS in the dose reduction group was significantly prolonged compared with that in the standard dose group (26.0 months vs. 12.0 months, p = 0.03). Multivariable analysis of 84 patients, excluding a patient with unknown brain metastasis, revealed that EGFR exon 21 L858R mutation, malignant pleural effusion or pleural metastasis, liver metastasis, and dose reduction within 6 months were independent factors affecting PFS. Early dose reduction of osimertinib is an effective therapeutic strategy for prolonging PFS in patients with EGFR-mutated NSCLC.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR L858R + EGFR exon 21 deletion
|
Tagrisso (osimertinib)
2d
PolyDamas: A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=80, Recruiting, Janssen Research & Development, LLC | Trial completion date: Nov 2025 --> Aug 2026
Trial completion date • Combination therapy • Metastases
|
EGFR L858R • EGFR exon 19 deletion
|
Rybrevant (amivantamab-vmjw) • cetrelimab (JNJ-63723283)
2d
CHRYSALIS: Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=751, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2024 --> Jun 2025
Trial completion date • Metastases
|
ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • EGFR C797S • MET mutation • MET expression • EGFR exon 20 mutation • EGFR positive
|
carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
4d
Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lung. (PubMed, Kaohsiung J Med Sci)
In summary, ramucirumab may have similar effectiveness as bevacizumab in combination with an EGFR-TKI as first line therapy for advanced lung adenocarcinoma harboring susceptible EGFR mutation. Further large-scale registry-based cohort studies may be needed to validate our findings.
Clinical data • Journal • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Avastin (bevacizumab) • Cyramza (ramucirumab)
4d
Enrollment change • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR L861Q
|
NX-019
4d
Structural analysis of the macrocyclic inhibitor BI-4020 binding to EGFR kinase. (PubMed, ChemMedChem)
Structures show that BI-4020 is likely rendered selective due to interactions with the kinase domain hinge region as well as T790M, akin to Osimertinib. Additionally, BI-4020 is also rendered more potent due to its constrained macrocycle geometry as well as additional H-bonds to conserved K745 and T845 residues in both active and inactive conformations. These findings taken together show how this novel macrocyclic inhibitor is both highly potent and selective for mutant EGFR in a reversible mechanism and motivate structure- inspired approaches to developing targeted therapies in medicinal oncology.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR C797S
|
Tagrisso (osimertinib) • BI-4020
6d
PTEN decreases NR2F1 expression to inhibit ciliogenesis during EGFRL858R-induced lung cancer progression. (PubMed, Cell Death Dis)
PTEN acts as a double-edged sword that differentially regulates EGFRL858R-induced lung cancer progression in different genomic backgrounds. Understanding the PTEN in lung cancer with different genetic backgrounds will be beneficial for therapy in the future.
Journal
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • PTEN (Phosphatase and tensin homolog) • NR2F1 (Nuclear Receptor Subfamily 2 Group F Member 1)
|
KRAS mutation • EGFR mutation • EGFR L858R • PTEN expression • PTEN overexpression • PTEN negative
7d
An epidermal growth factor receptor compound mutation of L858R with S768I in advanced non-small-cell lung cancer: a case report. (PubMed, J Med Case Rep)
This case report is a compelling testimony to the evolving therapeutic landscape of non-small cell lung cancers, providing valuable insight into the potential therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in the realm of rare and complex epidermal growth factor receptor mutations.
Journal • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR S768I • EGFR L858R + EGFR S765I
|
Gilotrif (afatinib)
7d
All-In-One OsciDrop Digital PCR System for Automated and Highly Multiplexed Molecular Diagnostics. (PubMed, Adv Sci (Weinh))
Moreover, the digital stepwise melting analysis (dSMA) technique is introduced, enabling high-multiplex profiling of seven major EGFR variants spanning 35 subtypes. This innovative dPCR system presents a cost-effective and versatile alternative, overcoming existing limitations and paving the way for transformative advances in precision diagnostics.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
8d
Furmonertinib and intrathecal pemetrexed chemotherapy rechallenges osimertinib-refractory leptomeningeal metastasis in a non-small cell lung cancer patient harboring EGFR20 R776S, C797S, and EGFR21 L858R compound EGFR mutations: a case report. (PubMed, Anticancer Drugs)
Regrettably, the patient eventually died from heart disease. This report provides the first reported evidence for the use of furmonertinib and intrathecal pemetrexed chemotherapy in NSCLC patients harboring EGFR R776S/C797S/L858R mutations who progressed on previous EGFR-TKIs.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR C797S
|
Tagrisso (osimertinib) • pemetrexed • Ivesa (furmonertinib)
8d
EGFR exon 18 delE709_T710insD mutated stage IV non-small cell lung cancer treated with osimertinib: a case report. (PubMed, Anticancer Drugs)
This specific mutation in exon 18 seems to respond to certain EGFR TKIs such as afatinib. However, given the rarity of this mutation, determining the most effective TKI for its treatment remains unclear. We report a 70-year-old woman diagnosed with stage IV-A lung adenocarcinoma harboring EGFR delE709_T710insD mutation treated in first-line with Osimertinib using standard schedule and doses experiencing renal toxicity and disease progression after 9 weeks of treatment.
Journal • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 18 mutation • EGFR E709_T710delinsD • EGFR delE709_T710insD
|
Tagrisso (osimertinib) • Gilotrif (afatinib)
10d
Trial completion date • Real-world evidence • Real-world • Metastases
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification
|
Tagrisso (osimertinib)
11d
Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice? (PubMed, Transl Lung Cancer Res)
Median overall survival (95% CI) was 21.30 (15.86-26.75) months. Lower afatinib doses (<40 mg OD) could be equally effective as standard dose in patients with EGFR-mutant advanced NSCLC and may be more suited to Asian patients, minimizing side effects that may occur at higher dosages of afatinib leading to dose interruptions and affecting treatment outcomes.
Journal • Real-world evidence • Real-world • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L858R + EGFR exon 21 deletion
|
Gilotrif (afatinib)
11d
Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer. (PubMed, Heliyon)
In first-generation EGFR-TKIs treatment, gefitinib showed favorable efficacy compared to icotinib and erlotinib, particularly in patients with EGFR L858R mutations...In third-line treatments, the combination of osimertinib and anlotinib demonstrated superior efficacy compared to other regimens. Glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) mutation was an independent risk indicator of shorter OS following third-line treatments. Comprehending the tumor evolution in NSCLC is advantageous for assessing the efficacy and prognosis at each stage of treatment, providing valuable insights to guide personalized treatment decisions for patients.
Journal
|
POLE (DNA Polymerase Epsilon) • IKZF1 (IKAROS Family Zinc Finger 1) • RBM10 (RNA Binding Motif Protein 10) • RAC1 (Rac Family Small GTPase 1) • EPHA3 (EPH receptor A3) • RAD21 (RAD21 Cohesin Complex Component) • GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • PAK1 (p21 (RAC1) activated kinase 1) • PAK5 (P21 (RAC1) Activated Kinase 5)
|
EGFR mutation • EGFR L858R • GRIN2A mutation • RBM10 mutation
|
Tagrisso (osimertinib) • erlotinib • gefitinib • Focus V (anlotinib) • Conmana (icotinib)
11d
Trial completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Tagrisso (osimertinib) • erlotinib • gefitinib • Cyramza (ramucirumab)
12d
Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinomas in European Patients Have Less KRAS and More EGFR Mutations Compared to Advanced Adenocarcinomas. (PubMed, Int J Mol Sci)
The EGFR exon 19 deletion mutation was more common in both MIA (50%; n = 6/12) and ADC (41%; n = 149/363), whereas p.L858R was more prevalent in AIS (75%; n = 3/4). In contrast to pulmonary advanced ADC, KRAS driver mutations are less common, whereas mutations in EGFR are more common, in detectable AIS and MIA.
Journal • Metastases
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • EGFR mutation • KRAS G12C • EGFR L858R • EGFR exon 19 deletion • KRAS G12
13d
USP24-i-101 targeting of USP24 activates autophagy to inhibit drug resistance acquired during cancer therapy. (PubMed, Cell Death Differ)
USP24 functional knockout, USP24C1695A, or targeting USP24 by USP24-i-101 inhibited drug resistance and activated autophagy in gefitinib-induced drug-resistant mice with doxycycline-induced EGFRL858R lung cancer, but this effect was abolished after inhibition of autophagy, indicating that targeting USP24-mediated induction of autophagy is required for inhibition of drug resistance. In addition, inhibition of autophagy by bafilomycin-A1 significantly abolished the effect of USP24-i-101 on maintaining genomic integrity, decreasing PD-L1 and inhibiting drug resistance acquired in chemotherapy or targeted therapy. In summary, an increase in the expression of USP24 in cancer cells is beneficial for the induction of drug resistance and targeting USP24 by USP24-i-101 optimized from USP24-i inhibits drug resistance acquired during cancer therapy by increasing PD-L1 protein degradation and genomic stability in an autophagy induction-dependent manner.
Journal • PD(L)-1 Biomarker • IO biomarker
|
TRAF6 (TNF Receptor Associated Factor 6)
|
EGFR L858R
|
gefitinib
14d
A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=53, Active, not recruiting, Takeda | Trial completion date: Mar 2024 --> Mar 2025
Trial completion date
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR A763_Y764insFQEA • EGFR exon 20 mutation
|
Exkivity (mobocertinib)
17d
Enrollment open • Trial initiation date
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R
|
Tagrisso (osimertinib)
17d
Trial completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS mutation • EGFR L858R • ALK rearrangement • RAS mutation
|
Keytruda (pembrolizumab) • docetaxel • Lenvima (lenvatinib)
17d
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. (PubMed, Target Oncol)
In both the primary stage II-IIIA and overall stage IB-IIIA populations, patients in the osimertinib group had a significant 51% reduction in the risk of death compared with the placebo group. The data demonstrated that osimertinib after surgery significantly improved overall survival in patients with resected, EGFR-mutated, stage IB-IIIA NSCLC.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Tagrisso (osimertinib)
21d
Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study). (PubMed, Ther Adv Med Oncol)
Median disease-free survival (DFS) and overall survival were not reached and 3-year DFS was 60%. This real-world analysis provides the incidence and outcomes of resected EGFR-mutated NSCLCs in a European patient cohort.
Journal • PD(L)-1 Biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • EGFR mutation • EGFR L858R
21d
Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial. (PubMed, Lung Cancer)
In this real-world population, nearly half of patients would have been ineligible for FLAURA. The mOS was one year shorter than reported in FLAURA. However, patients who would have been eligible for the FLAURA clinical trial had similar OS to patients enrolled in FLAURA. Trial ineligible patients had a higher burden of disease at baseline which may have led to inferior outcomes. Further research is needed to improve outcomes in these patients.
Journal • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R
|
Tagrisso (osimertinib)
23d
Use of Streck nucleic acid BCT with plasma nucleic acid next-generation sequencing workflows (AACR 2024)
Our data demonstrate that Nucleic Acid BCT maintains mutant allele frequencies and the plasma transcriptome profile of blood samples during ambient temperature storage. This provides precious sample integrity during whole blood storage and transport, offering laboratories and assay developers reduced preanalytical variability for NGS-based analysis of gene mutations, fusions, indels, and the plasma transcriptome. Nucleic Acid BCT is for Research Use Only.
Next-generation sequencing
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • EGFR mutation • PIK3CA mutation • EGFR L858R • KRAS G12D • KRAS G12 • PIK3CA E545
|
TruSight Tumor 15 Assay
23d
Reliable detection of potentially therapeutically actionable ecDNA using clinical-grade NGS in a large pan-cancer cohort (AACR 2024)
The results demonstrate that detection of ecDNA using clinical-grade NGS assays is feasible and that key oncogene FH-amp on ecDNA (e.g., EGFR, FGFR2) are common in select tumor types. ECHO may be developed as a clinical trial device to prospectively identify patients with oncogene ecDNA+ FH-amp for clinical testing of ecDNA-directed therapies.
Clinical • Next-generation sequencing • BRCA Biomarker • Pan tumor
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • FGFR2 (Fibroblast growth factor receptor 2) • EML4 (EMAP Like 4) • FGFR1 (Fibroblast growth factor receptor 1) • CCNE1 (Cyclin E1) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CDK4 (Cyclin-dependent kinase 4) • BRCA (Breast cancer early onset) • MDM4 (The mouse double minute 4) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)
|
EGFR mutation • EGFR L858R • ALK fusion
|
MSK-IMPACT
25d
TATTON: AZD9291 in Combination With Ascending Doses of Novel Therapeutics (clinicaltrials.gov)
P1, N=344, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date • Combination therapy • Metastases
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
|
Tagrisso (osimertinib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • Orpathys (savolitinib)
26d
Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201. (PubMed, Lung Cancer)
This analysis demonstrated long-term clinical benefit with lazertinib 240 mg in patients with EGFR-mutated NSCLC who had not previously received EGFR TKIs. The safety profile for lazertinib was tolerable and consistent with that previously reported.
Journal • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR G719X
|
Leclaza (lazertinib)
27d
Premedication to Reduce Amivantamab Associated Infusion Related Reactions (clinicaltrials.gov)
P2, N=67, Recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2025 --> Aug 2026
Trial completion date
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • dexamethasone • Leclaza (lazertinib)
27d
MET overexpression correlated with prognosis of EGFR-mutant treatment‑naïve advanced lung adenocarcinoma: a real‑world retrospective study. (PubMed, Clin Transl Oncol)
MET positive expression was an independent predictor of poor outcomes in untreated EGFR L858R mutation advanced LUAD patients treated with first-line EGFR-TKI monotherapy.
Retrospective data • Journal • Real-world evidence • Real-world • Metastases
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR expression • MET overexpression • EGFR L861Q • EGFR S768I • MET expression • MET positive • EGFR G719A • EGFR G719C
29d
Enrollment open
|
EGFR (Epidermal growth factor receptor)
|
EGFR L858R • EGFR exon 19 deletion
|
Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
30d
A Retrospective Real-World Study of Prognostic Factors Associated With EGFR Mutated Lung Cancer With Leptomeningeal Metastasis. (PubMed, Clin Lung Cancer)
Among NSCLC-LM patients with EGFR mutation, receiving EGFR-TKI combined with antiangiogenic therapy may result in a better survival benefit. The factors of primary LM, combined brain metastasis may be prognostic factors for poor OS.
Retrospective data • Journal • Real-world evidence • Real-world
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Avastin (bevacizumab)
30d
MELROSE: MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib (clinicaltrials.gov)
P2, N=150, Active, not recruiting, Nantes University Hospital | Recruiting --> Active, not recruiting | N=66 --> 150 | Trial completion date: Jul 2024 --> Jan 2025 | Trial primary completion date: Apr 2024 --> Jan 2025
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Liquid biopsy • IO biomarker • Metastases • Biopsy
|
HER-2 (Human epidermal growth factor receptor 2)
|
EGFR mutation • HER-2 amplification • EGFR L858R • EGFR exon 19 deletion
|
Tagrisso (osimertinib)
1m
The safety and efficacy of anti-PD-1 inhibitor-based combinational therapy in non-small cell lung cancer patients with oncogenic alterations. (PubMed, Transl Cancer Res)
The anti-PD-1 inhibitor-based combinational therapy elicited exciting anti-tumor efficacy and prolonged patient survival with manageable adverse effects in NSCLC patients harboring oncogenic alterations. The PD-L1 status and LIPI could be used as a biomarker predicting response to anti-PD-1 inhibitor-based combinational treatment in these patients.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene)
|
BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR L858R • ALK rearrangement • HER-2 exon 20 insertion • RAS mutation • RET mutation • RET rearrangement • HER-2 exon 20 mutation • EGFR L858R + EGFR exon 21 deletion • HER-2 exon 23 mutation
1m
Anticancer Evaluation of Novel Benzofuran-Indole Hybrids as Epidermal Growth Factor Receptor Inhibitors against Non-Small-Cell Lung Cancer Cells. (PubMed, Pharmaceuticals (Basel))
In addition, in PC9 and A549 cells, 8aa potently blocked the EGFR signaling pathway, cell viability, and cell migration. These findings suggest that 8aa, a benzofuran-indole hybrid derivative, is a novel EGFR inhibitor that may be a potential candidate for the treatment of NSCLC patients with EGFR mutations.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR T790M
1m
The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs. (PubMed, Front Oncol)
TP53/EGFR co-mutation patients receiving first-line EGFR-TKI treatment had poor prognoses in advanced LUAD, especially with L858R mutation. Moreover, TP53/EGFR co-mutation patients treated with EGFR-TKIs may more easy developed intracranial metastasis.
Journal • Metastases
|
TP53 (Tumor protein P53)
|
TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • TP53 wild-type
1m
Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis. (PubMed, JTO Clin Res Rep)
HRQoL was maintained from baseline, and safety was consistent with the global population. In this population of Chinese patients from ADAURA, adjuvant osimertinib was found to have a clinically meaningful improvement in DFS versus placebo, with maintained HRQoL and a safety profile consistent with the global study population.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Tagrisso (osimertinib)
1m
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) With Osimertinib for the Treatment of Patients With Oligoprogressive EGFR Positive Non-small Cell Lung Carcinoma (clinicaltrials.gov)
P2, N=32, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: May 2025 --> Jul 2026 | Initiation date: Dec 2023 --> Jun 2024 | Trial primary completion date: May 2025 --> Jul 2026
Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
|
Tagrisso (osimertinib)
1m
Synthesis and preclinical evaluation of [11C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptor. (PubMed, EJNMMI Res)
EAI045 was successfully labeled with tritium and carbon-11, and the in vivo results indicated [11C]EAI045 may be able to distinguish between mutated and non-mutated EGFR in non-small cell lung cancer mouse models. Cetuximab was hypothesized to increase EAI045 uptake; however, no significant effect was observed on the uptake of [11C]EAI045 in vivo or [3H]EAI045 in vitro in H1975 xenografts and cells.
Preclinical • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR expression • EGFR wild-type • EGFR L858R + EGFR T790M • EGFR H1975
|
Erbitux (cetuximab)
1m
Is there a prognostic difference among stage I lung adenocarcinoma patients with different BRAF-mutation status? (PubMed, Thorac Cancer)
In this study, we demonstrated that BRAF status may not be capable of predicting prognosis in stage I LUAD patients. There is a need for more data to validate our findings.
Journal
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
|
BRAF V600E • EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • BRAF wild-type
1m
Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations. (PubMed, JTO Clin Res Rep)
In addition, the probability of disease progression over time was higher for L858R compared with that for exon 19 deletion mutation, in patients with central nervous system metastasis (log-rank test, p = 0.027). The mutation subtype had an impact not only on the clinical outcome of the first-line OSI treatment but also on progression patterns after OSI treatment in patients with NSCLC harboring EGFR mutations.
Journal • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L858R + EGFR exon 21 deletion
|
Tagrisso (osimertinib)
1m
ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (clinicaltrials.gov)
P2, N=95, Active, not recruiting, ETOP IBCSG Partners Foundation | Trial primary completion date: Dec 2023 --> Mar 2024
Trial primary completion date
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR G719X • EGFR S768I
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • paclitaxel • pemetrexed